Patents by Inventor Herbert F. Oettgen
Herbert F. Oettgen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5643550Abstract: This invention provides a method of imaging a colorectal carcinoma lesion in a human patient which comprises administering to the patient a monoclonal antibody capable of binding to a cell surface antigen associated with the colorectal carcinoma lesion and which is labeled with an imaging agent under conditions so as to form a complex between the monoclonal antibody and the cell surface antigen, imaging any complex so formed, and thereby imaging the colorectal carcinoma lesion.This invention also provides a monoclonal antibody designated AS 33 (ATCC Accession No. HB 8779) and the hybridoma which produces it.Type: GrantFiled: September 27, 1994Date of Patent: July 1, 1997Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Sydney Welt, Chaitanya R. Divgi, Samual Yeh, Lloyd J. Old, Herbert F. Oettgen, Francisco X. Real, Junichi Sakamoto
-
Patent number: 5431897Abstract: This invention provides a method of imaging a colorectal carcinoma lesion in a human patient which comprises administering to the patient a monoclonal antibody capable of binding to a cell surface antigen associated with the colorectal carcinoma lesion and which is labeled with an imaging agent under conditions so as to form a complex between the monoclonal antibody and the cell surface antigen, imaging any complex so formed, and thereby imaging the colorectal carcinoma lesion.This invention also provides a monoclonal antibody designated AS 33 (ATCC Accession No. HB 8779) and the hybridoma which produces it.Type: GrantFiled: February 16, 1993Date of Patent: July 11, 1995Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Sydney Welt, Chaitanya R. Divgi, Samual Yeh, Lloyd J. Old, Herbert F. Oettgen, Francisco X. Real, Junichi Sakamoto
-
Patent number: 5160723Abstract: This invention provides a method of imaging a colorectal carcinoma lesion in a human patient which comprises administering to the patient a monoclonal antibody capable of binding to a cell surface antigen associated with the coloretal carcinoma lesion and which is labeled with an imaging agent under conditions so as to form a complex between the monoclonal antibody and the cell surface antigen, imaging any complex so formed, and thereby imaging the colorectal carcinoma lesion.This invention also provides a monoclonal antibody designated AS 33 (ATCC Accession No. HB 8779) and the hybridoma which produces it.Type: GrantFiled: March 18, 1991Date of Patent: November 3, 1992Assignee: Sloan-Kettering Institute For Cancer ResearchInventors: Sydney Welt, Chaitanya R. Divgi, Samual Yeh, Lloyd J. Old, Herbert F. Oettgen, Francisco X. Real, Junichi Sakamoto
-
Patent number: 5102663Abstract: The present invention provides a vaccine for stimulating or enhancing in a subject to whom the vaccine is administered, production of antibodies directed against 9-O-acetyl GD3 ganglioside comprising an amount of purified 9-O-acetyl GD3 ganglioside effective to stimulate or enhance antibody productionThis invention was made with government support under Grant Numbers CA-40532 and CA-43971, National Cancer Institute, Department of Health and Human Services. Accordingly, the U.S. Government has certain rights in the invention.Type: GrantFiled: October 18, 1988Date of Patent: April 7, 1992Assignee: Sloan-Kettering Instutute for Cancer ResearchInventors: Philip O. Livingston, Gerd J. Ritter, Herbert F. Oettgen, Lloyd J. Old
-
Patent number: 5059523Abstract: This invention provides a method of identifying mesenchymal tissues as normal, proliferatively active or malignant. This invention also provides a method of distinguishing subsets of sarcomas with distinctive antigenic phenotypes. This invention also provides a method of diagnosing mesenchymal tumors. Finally, this invention provides a monoclonal antibody designated G171 and the hybridoma cell line producing said monoclonal antibody (ATCC No. HB9254).Type: GrantFiled: May 2, 1988Date of Patent: October 22, 1991Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Wolfgang J. Rettig, Pilar Garin-Chesa, H. Richard Beresford, Herbert F. Oettgen, Myron R. Melamed, Lloyd J. Old
-
Patent number: 5006470Abstract: This invention provides a monoclonal antibody, produced by the hybridoma cell line designated GXM1, which specifically binds to a human class 1tumor antigen. This invention also provides a human monoclonal antibody, produced by a hybridoma cell line designated HJM1, which specifically binds to each of the ganglioside antigens GD2, GD3, GM3 and GD1b. This invention further provides a human monoclonal antibody, produced by a hybridoma cell line designated FCM1, which specifically binds to the ganglioside antigens GM3 and GD1a. Finally, this invention provides a human monoclonal antibody, produced by a hybridoma cell line designated DSM1, which specifically binds to a human class 2 tumor protein antigen.Type: GrantFiled: April 16, 1987Date of Patent: April 9, 1991Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Hiroshi Yamaguchi, Koichi Furukawa, Philip O. Livingston, Kenneth O. Lloyd, Herbert F. Oettgen, Lloyd J. Old, Sheila R. Fortunato
-
Patent number: 4935344Abstract: Antigenic profiles of renal carcinoma specimans developed with panels of monoclonal antibodies derived from several different tissues serve as useful clinical indicators for cancer type, cancer subset as well as histiogenesis and prognosis indicators.Type: GrantFiled: March 7, 1986Date of Patent: June 19, 1990Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Neil H. Bander, Carlos Cordon-Cardo, Connie L. Finstad, Willet F. Whitmore, Myron R. Melamed, Herbert F. Oettgen, Lloyd J. Old
-
Patent number: 4865998Abstract: A panel of monoclonal antibodies produced from normal human lung fibroblasts and human lung tumors as immunogen is used to diagnose the presence of lung tumors and differentiate between those which are benign and those which are cancerous.Type: GrantFiled: August 10, 1987Date of Patent: September 12, 1989Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Hans-Joachim Feickert, Wolfgang Rettig, Karen Chorney, Carlos Cordon-Cardo, Myron R. Melamed, Kenneth O. Lloyd, Herbert F. Oettgen, Lloyd J. Old, Bernd Anger
-
Patent number: 4851332Abstract: Monoclonal antibodies to specific cell surface antigens of human choriocarcinoma, teratocarcinoma, and normal trophoblasts are disclosed. Additionally, panels of monoclonal antibodies which may be used in phenotyping cell and tissue samples are disclosed as well.Type: GrantFiled: April 1, 1985Date of Patent: July 25, 1989Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Wolfgang J. Rettig, Carlos Cordon-Cardo, John P. Koulos, John L. Lewis, Jr., Herbert F. Oettgen, Lloyd J. Old
-
Patent number: 4808704Abstract: Monoclonal antibody recognizing human melanoma cells, method of production and use.Type: GrantFiled: May 22, 1986Date of Patent: February 28, 1989Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Lloyd J. Old, Herbert F. Oettgen, Hisami Ikeda, Lucy T. C. Li, Kenneth O. Lloyd, Wolfgang G. Dippold
-
Patent number: 4762800Abstract: Antibody-producing hybridoma cell lines made by fusion of NS/1 cells with spleen cells of mice after immunization with human teratocarcinoma cells are presented. Monoclonal antibodies from these cell lines recognize the K4, K2 and P12 antigenic systems and are thus useful in detecting and differentiating between normal and cancerous cells. These monoclonal antibodies are especially useful in pathologic analysis of human tumors, especially teratocarcinomas.Type: GrantFiled: April 26, 1984Date of Patent: August 9, 1988Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Wolfgang Rettig, Carolos Cordon-Cardo, Herbert F. Oettgen, Lloyd J. Old, Kenneth O. Lloyd, Jennifer Ng
-
Patent number: 4727021Abstract: Human monoclonal antibodies (HmAbs) capable of reacting with cytokeratin are disclosed. It has been found that HmAbs De8, M54, M307, Hull, C29, Hu22 and Pa24 may be used to detect these cytoskeletal proteins in various cells. By means of these HmAbs the embryological origin of cells may be determined. This information may be used to determine the possible tissue source of metastasized tumors and greatly affects the management of these cancers.Type: GrantFiled: June 1, 1984Date of Patent: February 23, 1988Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Richard J. Cote, Timothy M. Thomson, Alan N. Houghton, Herbert F. Oettgen, Lloyd J. Old
-
Patent number: 4695538Abstract: Human monoclonal antibodies (HmAbs) capable of reacting with cell surface antigens and intracellular components are disclosed. It has been found that HmAbs Ev248, Ch-5, Ch-13, Te-39, Hu44, Ge-1, Gr-431, Gr169 and Sp909 may be used to detect these antigens in various cells. By means of these HmAbs malignant cells may be determined. This information may be used to screen metastasized tumors and primary tumors for tissue source and greatly affects the management of these cancers.Type: GrantFiled: June 1, 1984Date of Patent: September 22, 1987Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Richard J. Cote, Timothy M. Thomson, Alan N. Houghton, Herbert F. Oettgen, Lloyd J. Old, Carlos C. Cardo
-
Patent number: 4693966Abstract: Human monoclonal antibodies which specifically bind to antigens found on cell surfaces of renal, lung, and breast cancer cells, intracellular cytoskeletal antigens, nuclear antigens, and cytoplasmic reticular antigens are disclosed. The antibodies are the product of hybridoma cell lines, where the immortal cell line may be, e.g., a human cell line, or a murine cell line.Type: GrantFiled: March 11, 1983Date of Patent: September 15, 1987Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Alan N. Houghton, Hannah Brooks, Richard J. Cote, Herbert F. Oettgen, Lloyd J. Old
-
Patent number: 4678747Abstract: Monoclonal antibodies recognizing the difucosyl-type-2-H antigen on human cells and a method of producing said antibodies are disclosed. The monoclonal antibodies are useful in blood typing and in diagnosis of blood disorders and malignancies involving loss or gain of this H antigen.Type: GrantFiled: February 28, 1983Date of Patent: July 7, 1987Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Kenneth O. Lloyd, Lloyd J. Old, Karl-Anders Karlsson, Goran Larson, Nicklas Stromberg, Jan Thurin, Bernd R. Anger, Herbert F. Oettgen
-
Patent number: 4650756Abstract: The preparation and use of monoclonal antibodies to human renal tumor cells is described. The monoclonal antibodies bind to glycoproteins of 160Kd, 120Kd and 115Kd, a glycolipid, a HLA heavy chain, group A blood and group B blood antigens.Type: GrantFiled: August 31, 1981Date of Patent: March 17, 1987Assignee: Sloan Kettering Institute for Cancer ResearchInventors: Lloyd J. Old, Kenneth O. Lloyd, Herbert F. Oettgen, Willet F. Whitmore, Jerzy Szkudlarek, Connie L. Finstad, Donna Morrissey, Shun-ichiro Ogata, Ryuzo Ueda
-
Patent number: 4613576Abstract: Hybridomas which produce human monoclonal antibodies are disclosed. The hybridomas are formed by fusing lymphocytes from individuals with various cancers to an immortal cell line, such as a myeloma, from, e.g., a human cell line, or a mouse cell line.Type: GrantFiled: March 9, 1983Date of Patent: September 23, 1986Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Richard J. Cote, Donna M. Morrissey, Alan N. Houghton, Edward J. Beattie, Jr., Herbert F. Oettgen, Lloyd J. Old
-
Patent number: 4579827Abstract: A panel of monoclonal antibodies produced from human gastrointestinal tumors as immunogen is used to diagnose the presence of colon cancer. The antibody panel subsets the human gastrointestinal tract in its reactivity vis-a-vis esophagus, stomach, small intestine and colon. The panel is useful as a diagnostic probe for cancer.Type: GrantFiled: March 11, 1983Date of Patent: April 1, 1986Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Junichi Sakamoto, Carlos Cordon-Cardo, Eileen Friedman, Connie L. Finstad, Warren E. Enker, Myron R. Melamed, Kenneth O. Lloyd, Herbert F. Oettgen, Lloyd J. Old
-
Patent number: 4562160Abstract: The present invention concerns novel immunoprecipitating autologous antibodies which recognize the Class 1 gp90 antigen on melanoma cells. These antibodies, optionally tagged with a chromophoric or radioactive label and immobilized on an inert support, may be used to recognize and isolate the gp90 antigen from melanoma cell extracts. Monoclonal antibodies to melanoma may be screened with the gp90 antigen for those which recognize epitopes other than the FD antigenic system.The cell line containing the gp90 antigen which has been cultured in vitro is a source of gp90 antigen for generation of monoclonal antibodies which will be useful in analyzing the gp90 antigen for those epitopes which may be of diagnostic value in immunoassay of melanoma.Type: GrantFiled: April 1, 1983Date of Patent: December 31, 1985Assignee: Sloan-Kettering InstituteInventors: Francisco X. Real, M. Jules Mattes, Alan N. Houghton, Philip O. Livingston, Kenneth O. Lloyd, Herbert F. Oettgen, Lloyd J. Old
-
Patent number: 4507391Abstract: Mouse monoclonal antibody AbR.sub.24 (Dippold et al., Proc. Natl. Acad. Sci. 77:6114-6118, 1980) has a high degree of specificity for human melanoma cells when tested on viable cultured cells using the PA-MHA serological assay. The antigen detected by this antibody has been isolated from melanoma cells and shown to be G.sub.D3 ganglioside by compositional and partial structural analysis and by comparison with authentic G.sub.D3 by thin layer chromatography (TLC). AbR.sub.24 reacts with authentic G.sub.D3, but not with any other ganglioside tested. Using TLC and reactivity with AbR.sub.24, a wide range of cells and tissues was examined for the presence of G.sub.D3. A new serological assay, termed glycolipid-mediated immune adherence (GMIA), was devised for assaying the reactivity of AbR.sub.24 with gangliosides. Melanomas (cultured cells or tumor tissue) were shown to have T.sub.D3 and G.sub.M3 as major gangliosides. Other cells and tissues examined also contained G.sub.D3, but usually only in low amounts.Type: GrantFiled: April 2, 1982Date of Patent: March 26, 1985Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Clifford S. Pukel, Kenneth O. Lloyd, Luiz R. Travassos, Wolfgang G. Dippold, Herbert F. Oettgen, Lloyd J. Old